Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

Completed · Phase 4

Conditions studied: Coronary Artery Disease, Type 2 Diabetes Mellitus

In brief

The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type 2 diabetes. The primary hypothesis is that aliskiren will reduce these biomarkers compared to a calcium channel blocker.

Key facts

Study ID

NCT00818779

Run by

Texas Tech University Health Sciences Center

People needed

38

Starts

2008-01-01

Expected to finish

2011-08-01

Last updated by the study team

2017-12-05

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of type 2 diabetes
• Diagnosis of coronary artery disease
• Currently receiving therapy with an ACE-Inhibitor or Angiotensin Receptor Blocker
• Currently receiving antiplatelet therapy and statin therapy
• Baseline blood pressure > 100/75 mm Hg
• BMI 25-35 kg/m2

You may not qualify if…

• Concurrent calcium channel blocker therapy
• Documented peripheral edema
• Hyperkalemia
• Serum creatinine > 2.0
• Diagnosed with proteinuria
• Diagnosed with liver dysfunction or serious rheumatological disorder

Where it is running

• Texas Tech University Health Sciences Center — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.